Our
pipeline
 
 
     
     
  Our areas of focus

Our products

Research & Development
 
     
     
 
Our pipeline is the lifeblood and the future of the company.

We have an extremely productive pharmaceutical pipeline, with 50 compounds in development. Our pipeline has been described as the “most improved” in the industry by the US magazine R&D Directions.

To ensure our pipeline is sustainable, our focus is threefold. We aim to:

  • Improve productivity in the discovery process
  • Deliver a constant stream of high-quality candidate medicines for clinical tests
  • Enhance success rates of drugs in development

The chart below illustrates the number of compounds we have in different stages of development. Click here to view this larger.

Late-stage pipeline
A significant proportion of our research and development expenditure goes on our late-stage pipeline products. We anticipate these medicines being available in the UK over the next few years.

Product Therapeutic Area
Orencia® (abatacept) and Belatacept Immunology
   
Atripla® (efavirenz, emtricitabine, tenofovir disoproxil fumarate) Anti-infectives
(Joint venture between Bristol-Myers Squibb and Gilead Sciences in the UK)
   
Ixabepilone, ipilimumab, Javlor® (vinflunine) Cancer
   
Saxagliptin Metabolic Disorders
   
Apixaban Cardiovascular

 

 

   
 
     
     
   
     
     
   
   
     
 
   
     
 
   
     
     
 
© 2007 Bristol-Myers Squibb Pharmaceuticals Limited.
All corporate and product names or logos referenced in this Site are trademarks of Bristol-Myers Squibb, its global affiliates or its affiliates and are protected by international trademark laws. All rights reserved.
Your use of this site is subject to the Legal Terms and Privacy Policy.

Bristol-Myers Squibb Pharmaceuticals Limited Registered Office: Uxbridge Business Park, Sanderson Road, Uxbridge, Middlesex UB8 1DH
Company No: 02487574
A company registered in England and Wales.
 
 
Site Map Privacy Policy Legal Terms Contact us

Revision date: February 07 WEB/0207/0001/0109